NN 344
Alternative Names: NN344Latest Information Update: 16 Jan 2008
At a glance
- Originator Novo Nordisk
- Class Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 16 Jan 2008 Discontinued - Phase-I for Type-1 diabetes mellitus in Denmark (SC)
- 16 Jan 2008 Discontinued - Phase-I for Type-2 diabetes mellitus in Denmark (SC)
- 12 Jan 2006 Changed indication Diabetes mellitus to Type-1 and Type-2 diabetes mellitus as per Novo Nordisk's R&D Pipeline (Website, 11/01/2006)